Adjuvo: adjuvant mitotane in patients with AC and low-intermediate risk of recurrence post-surgery
0 Views
administrator
07/11/23
Jen-Jane Liu, MD, Oregon Health and Science University, Portland, OR, discusses the Adjuvo trial investigating mitotane in patients with adrenocortical carcinoma with low-intermediate risk of recurrence following surgery. The trial did not meet the primary endpoint of showing a benefit to adjuvant therapy in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
-
Category
Show more
Facebook Comments
No comments found